In addition, recent reports have shown that systemic CD4+ T cells influence positively ICI outcomes [160] and that a repertoire of pre-existing blood CD4+ T cells predicts better clinical outcomes in melanoma patients treated with anti-CTLA-4 [161]. Here, CD4 is linked to melanoma.